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Identity 
Other names: FLJ10385; TCAB1; WDR79 




The WRAP53 gene encompasses 16 kb of DNA; 13 
exons (three non-coding alternative start exons: exon 
1alpha, 1beta and 1gamma. Exon 1alpha directly 
overlaps the first exon of TP53 in an antisense fashion 
by up to 227 base pairs (bp), depending on transcription 
start site (TSS) usage. Exon 1gamma of WRAP53 is 
located in the first intron of TP53 overlapping the 
previously identified transcript Hp53int1 in an 
antisense fashion. 
Transcription 
At least 17 splice variants. 1.9 kb mRNA; 1647 bp 
open reading frame. 
Regulatory antisense RNA 
Expression: widely expressed at low levels. 
Localisation: cytoplasm and nucleus. 
Function: regulates p53 mRNA levels by interacting 
with the 5'UTR of p53 mRNA. 
Homology: conserved in mouse. 









548 amino acids; 75 kDa protein; contains from N-term 
to C-term, a proline-rich region (aa 8-57), a WD40 
domain, 5 repeats (160-441), and a glycin-rich region 
(533-545). 
Expression 
Widely expressed, overexpressed in cancer. 
Localisation 
Cytoplasm and nucleus (enriched in Cajal bodies). 
Function 
Essential for Cajal body formation and maintenance. 
Targets the SMN complex, scaRNAs and telomerase 
enzyme (via TERC) to Cajal bodies. Inhibition of 
WRAP53 triggers mitochondrial-dependent apoptosis 
specifically in cancer cells. 
Homology 
Highly-conserved in mammals, the WD40 domain is 
conserved from human to fly. 
Mutations 
Note 
Single nucleotide polymorphisms (SNPs) in women 

















Breast and ovarian cancer 
Note 
Single nucleotide polymorphisms (SNPs) in WRAP53 
were found to be overrepresented in women with breast 
cancer, in particular estrogen receptor negative breast 
cancer. The same SNPs were also associated with 
aggressive ovarian cancer. The SNPs are located in the 
coding region of WRAP53 and results in the amino 
acid change R68G. 
Spinal muscular atrophy (SMA) 
Note 
WRAP53 targets the SMN complex to Cajal Bodies. 
WRAP53 and SMN association is disrupted in SMA 
patients suggesting a role of WRAP53 in SMA 
pathogenesis. 
Disease 
Spinal muscular atrophy (SMA) is a common 
neurodegenerative disorder caused by reduced levels of 
SMN due to mutations or deletions of the SMN1 gene. 
SMA is the leading genetic cause of infant mortality 
worldwide, affecting approximately 1 in 6000 infants. 
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